IN RE: SUBOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE) ANTITRUST LITIGATION

  1. September 17, 2014

    Reckitt Says Suboxone 'Product-Hopping' Didn't Harm Buyers

    Reckitt Benckiser Group PLC's move to discontinue Suboxone tablets, in lieu of a new dissolving-film version of the opiate addiction treatment, presented no antitrust injury for classes of purchasers who claim they were denied generic alternatives, a Pennsylvania federal judge heard Wednesday.